糖尿病数字应用技术:EASD与ADA共识报告
欧洲糖尿病研究协会与美国糖尿病协会联合发布共识报告,综述独立糖尿病数字应用(不含胰岛素泵、CGM等受监管医疗器械的组成部分)的获益与挑战,指出欧美此类健康类应用多数不受监管,安全性与有效性证据有限。报告提出需由监管机构、政策制定者、专业组织、研究者、患者和医护人员共同解决的若干问题,并给出推荐行动。
要点
- 独立糖尿病数字应用在欧美多不受监管,除非符合医疗设备定义。
- 应用准确性、临床有效性证据不足,安全性与有效性证据有限。
- 报告提出系列推荐行动,涉及培训、互操作性、标准化与数据安全。
核心结论
- 糖尿病数字健康领域需基于最佳安全性与有效性证据发展,并解决监管、证据、培训、互操作、标准化与数据安全等多方面问题。
研究设计与样本
- EASD与ADA糖尿病技术工作组联合综述独立糖尿病数字应用(不含胰岛素泵、CGM、自动胰岛素输注系统等受监管医疗器械的组成部分)的现状及监管实践。
- 综述范围覆盖美国与欧洲的健康类移动应用监管情况以及国际组织(如国际医疗器械监管机构论坛和WHO)对数字健康技术的分类进展。
主要发现
- 在美国和欧洲,旨在管理健康与福祉的移动应用大多不受监管,除非符合治疗和/或诊断用途的医疗设备定义。
- 关于移动健康应用(尤其是糖尿病应用)安全性与有效性的现有证据仍然有限。
- 国际组织已在数字健康技术分类及将其纳入医疗器械领域方面取得进展。
临床怎么用
- 糖尿病社区(监管机构、政策制定者、专业组织、研究者、糖尿病患者和医护人员)需共同解决应用准确性、临床有效性证据不足、培训缺乏、互操作性差、标准化不足及数据安全不充分等问题。
- 报告提出一系列推荐行动以解决上述不足。
局限性
- 现有关于移动健康应用(尤其是糖尿病应用)安全性与有效性的证据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Digital health technology, especially digital and health applications ('apps'), have been developing rapidly to help people manage their diabetes. Numerous health-related apps provided on smartphones and other wireless devices are available to support people with diabetes who need to adopt either lifestyle interventions or medication adjustments in response to glucose-monitoring data. However, regulations and guidelines have not caught up with the burgeoning field to standardise how mobile health apps are reviewed and monitored for patient safety and clinical validity. The available evidence on the safety and effectiveness of mobile health apps, especially for diabetes, remains limited. The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have therefore conducted a joint review of the current landscape of available diabetes digital health technology (only stand-alone diabetes apps, as opposed to those that are integral to a regulated medical device, such as insulin pumps, continuous glucose monitoring systems, and automated insulin delivery systems) and practices of regulatory authorities and organisations. We found that, across the USA and Europe, mobile apps intended to manage health and wellness are largely unregulated unless they meet the definition of medical devices for therapeutic and/or diagnostic purposes. International organisations, including the International Medical Device Regulators Forum and WHO, have made strides in classifying different types of digital health technology and integrating digital health technology into the field of medical devices. As the diabetes digital health field continues to develop and become more fully integrated into everyday life, we wish to ensure that it is based on the best evidence for safety and efficacy. As a result, we bring to light several issues that the diabetes community, including regulatory authorities, policymakers, professional organisations, researchers, people with diabetes and healthcare professionals, needs to address to ensure that diabetes health technology can meet its full potential. These issues range from inadequate evidence on app accuracy and clinical validity to lack of training provision, poor interoperability and standardisation, and insufficient data security. We conclude with a series of recommended actions to resolve some of these shortcomings.
引用
- Fleming GA, Petrie JR, Bergenstal RM, et al. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia. 2020. PMID: 31802144. doi:10.1007/s00125-019-05034-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。